Carolyne Zimmermann

Carolyne Zimmermann has an extensive work experience in the pharmaceutical industry, with a focus on business development, licensing, and corporate strategy. Carolyne is currently working at SonoThera as the Chief Business Officer, a position they have held since June 2023. Prior to that, they worked as a Consulting CBO at SonoThera from January 2023 to May 2023.

Before joining SonoThera, Carolyne worked as an Independent Consultant specializing in corporate strategy and business development. Carolyne started this role in October 2022 and it is ongoing.

From June 2021 to September 2022, Carolyne served as the Chief Business Officer at 4D Molecular Therapeutics. Prior to that, they held various roles at Johnson & Johnson, including Vice President of Transactions at J&J Innovation from May 2016 to May 2021.

Carolyne also has experience as a General Partner at dRx Capital from January 2015 to April 2016. Carolyne began their career at Novartis Pharmaceuticals, where they held multiple roles, including Global Head of Business Development & Licensing for the Cardiovascular and Metabolic Diseases Franchise from 2011 to 2015.

Overall, Carolyne Zimmermann has a strong background in business development, corporate strategy, and licensing in the pharmaceutical industry.

Carolyne Zimmermann's education history includes an MBA in Finance & Management from Columbia Business School. Carolyne also has a background in Private Equity & Venture Capital from Harvard Business School. Additionally, they hold a Bachelor of Science in Engineering Science from UC San Diego. The specific start and end years for each educational experience are not provided.